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GLOSSARY 
ADT    -  androgen depr ivat ion therapy 
BCR    -  b iochemical  recurrence  
BPH   -  benign prostate hyperplas ia  
BCRF   -  b iochemical  recurrence f reedom  
BR   -  b iochemical  response  
BRFS   -  b iochemical  recurrence-f ree survival  
CAB    -  combined androgen b lockade  
CRFS   -  c l in ica l  recurrence-f ree survival  
CSM    -  cancer-spec if ic  morta l i t y  
CSS   -  cancer-spec if ic  survival  
EBRT    -  ex ternal beam radiotherapy 
EPCA-2   -  ear ly prostate cancer  ant igen-2 
ePLND  -  ex tended pelv ic lymph node d issect ion  
GS   -  Gleason score  
iPSA    -  in i t ia l  prostate spec if ic  ant igen  
HDR-BT  -  h igh-dose rate brachytherapy 
LHRH   -  lu te in izing hormone-re leas ing hormone 
LN   -  lymph node(s)  
LND    -  l ymph node d issect ion  
lPLND   -  l im ited pelv ic  lymph node d issect ion  
OS    -  overal l  survival  
PCa   -  prostate cancer  
PET/CT -  pos itron emission tomography /computer ized tomography  
PIN   -  prostate  in traepithel ia l neoplas ia  
PNLD   -  pelv ic lymph node dissect ion  
PSA    -  prostate spec if ic  ant igen  
PSA-DT   -  PSA doubl ing t ime 
PSM   -  pos it ive surgical  margin  
RS   -  re lat ive survival  
PW TRUS   -  power  doppler  transrecta l u ltrasonography  
RP    -  radical  prostatectomy 
RT    -  radiotherapy 
SePLND   -  sa lvage extended pelv ic lymph node d issect ion  
SgPLND   -  sent inel-guided pelvic lymph node d issect ion   
sRP    -  sa lvage radical  prostatectomy  
sRT   -  sa lvage radiotherapy 
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INTRODUCTION 
Prostate cancer (PCa) treatment has been one of  the cruc ial issues  in uro logy for 
decades. According to the U.S. «Cancer s tat ist ics  2009», the overal l  cancer death 
rates in men decreased by 19.2% between 1990 and 2005,  with a decrease in prostate 
cancer deaths by 24% (Jemal et a l.  2009).  According to «Cancer s tat is t ics 2010», PCa 
is  the most  common malignant  tumor in the male populat ion (est imated new cases 
217730, or 28%), and presents the second most  f requent cause of  death f rom cancer  
(11%) among Amer icans (Figure 1a)  (Jemal et  a l .  2010,  2011).  
The inc idence of  PCa increases much faster wi th age than the inc idence of  oth er 
malignant tumors, and unl ike them it  has no peak  (Jemal et a l.  2005). Thus the r isk  of 
acc identa l PCa among 50-year-old men is 27% (found dur ing autopsy af ter  decease 
f rom other causes) , among 80-year -o lds i t  is  63%. The r isk  of  PCa detect ion wi th a 
c l in ica l manifes tat ion is 3 .6%. Only 20% of  the d iagnosed prostate cancer  cases d ies 
f rom it .  The r isk  of  death f rom PCa among the whole men populat ion l ies at  2.0% 
(Stemmermann et a l.  1992).  Cl inica l manifestat ion  of  PCa is of ten asymptomat ic  and 
does not a lways present a threat to the l i fe of  the pat ient .  Occasional ly th is disease 
may proceed aggress ively, especia l ly in young pat ients , and -  in the absence of  t imely 
d iagnos is  and treatment  –  i t  may lead to death (Prest i  2000) .  
According to the 2011 cancer regis ter of  Schleswig-Hols tein, the number of  new PCa 
cases in 2008 was 2450 (25.6% of  the overal l  male cancer rate),  morta l i t y rate –  443 
(11.5% of  the overal l  cancer-re lated death rate)  (F igure 1b) .  In Germany,  the number 
of  new PCa cases in 2008 was 65582, making i t  the most f requent ly d iagnosed type of  
cancer  in  men (26.7%) (Pr i tzkule it  et  a l  2011).  
PCa usual ly proceeds f rom the per ipheral  zone of  the g land (65 %-90%). Invas ive 
cancer is  of ten preceded by PIN (prostat ic  in traepithel ia l neoplasia).  In contrast to 
PCa, the basal  layer  of  the epithel ium is safe dur ing PIN (Godoy and Taneja,  2008) .  
The choices of  treatment are re lat ive ly wel l  s tandardized. But treatment of  PCa 
recurrence and advanced d isease has encouraged a d iscuss ion concerning the 
opt imal method of  treatment . I t  is  wel l-known, that in some pat ients  the d isease takes 
a par t icu lar ly stubborn dr i f t  that  remains res istant to treatment or is  prone to recur  
shor t ly af ter  treatment  (Rober ts and Han 2009,  Moreira et  a l .  2010) .  
The character of  PCa c l in ica l development is  pr imar i ly determined by the 
character is t ics of  the tumor i tse lf :  the d isease stage according to the TNM-
classif icat ion, the Gleason score (GS) of  ce l l  d i f ferent iat ion, the level of  the prostate 
spec if ic  ant igen (PSA), and the PSA doubl ing-t ime (PSA-DT). The prognosis is  
determined by the presence of  metastases in the regional lymph nodes (LN) (s tage N),  
and by the presence of  d istant metastases (stage M). The lat ter  can be determined, 
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respect ive ly to the main types of  PCa metastas is . The in it ia l  metastat ic spread of  PCa 
is to the d istant LN, the secondary spread concerns  the bones and somet imes other  
internal organs (Heidenreich et a l.  2012) .   
Apar t f rom the LN,  the most f requent locat ion of  PCa metastases is in the  bones.  The 
ax ia l skeleton is involved in 85% of  those pat ients who die f rom PCa (W hitmore et a l .  
1984). Previous ly, bone sc int igraphy was a lways cons idered necessary dur ing PCa 
diagnost ics , but later i t  became clear  that th is  is  not required at PSA levels under 20 
ng/ml and in asymptomatic pat ients wi th well -  or  moderate ly-wel l  (GS up to 7a=3+4) 
d if ferent iated tumours  (Lee et a l.  2000) .   
PSA- levels below 10ng/ml were observed in 66% of  PCa pr imary pat ients according to 
one of  studies. I f  the in it ia l  PSA level was between 4ng/ml and 10ng/ml, PCa was 
found by b iopsy in 26%-35% pat ients. In these cases i t  is  impor tant to measure the 
f ree/ tota l PSA rat io  and PSA dens i ty (Horninger  et  a l .  2000,  I to  et  a l.  2003) .  
In other words, no carcinoma is detected in 64%-75% of  pat ients wi th «gray scale» 
PSA levels . Therefore, the number of  t issue samples in per  b iopsy was recent ly 
increased f rom 6 to 10, even in low-r isk  pat ients . The Vienna nomogram is a c l in ica l 
a lgor i thm, which can be used as a guide l ine for  d iagnos is  and treatment of  such 
pat ients (Heidenreich 2007) .  This nomogram determines the opt imal number of  
prostate b iops ies based on the pat ient ’s  age and the prostate volume (Remzi et a l . 
2005).  
The degree of  PCa t issue d if ferent iat ion is commonly judged by the system proposed 
by Dr.  D.F.  Gleason (Gleason et  a l .  1988) . I t  is  based on the microscopic s tructure of 
the g lands at a smal l  enlargement.  The degree of  d if ferent iat ion is  determined by two 
pr inc ipal  h is to logical  patterns –  f i rst ly the dominance, i .e.  ident i f icat ion of  the pattern 
that  occupies the largest area, and the second ly,  by the s ize  of  the pat tern . Each of  
these aspects  is est imated by a 5-point scale. By summing up both values, the tota l 
amount of  points is  obta ined. Thus, the GS can range f rom 2 to 10.  According to many 
authors , the GS is fundamental for  the prognos is of  the course of  the d isease and l i fe 
expectancy, a long with the PSA level and TNM stage (Roach 2003, Dall 'Ogl io et a l.  
2005,  Hsy et a l.  2009) .  
The Par t in Coef f ic ient Tables are another  important tool  in guiding dec is ions on 
ef fect ive t reatment opt ions for PCa. I t  is  a way of  predic t ing the cancer 's pathologic  
stage, which can only be determined af ter  the prostate g land has been removed by 
surgery and examined by a pathologis t.  There are  several Part in tables (nomograms) 
depending on the PSA level .  In one of  the f irst  nomograms based on data f rom 4133 
men treated for PCa, i t  was shown that the probabi l i t y of  having one of  the fol lowing 
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pathologic s tages of  PCa depends on PSA level ,  GS and c l in ica l stage  (Par t in et a l .  
1997):   
  Organ-conf ined d isease:  PCa complete ly conf ined to the prostate g land  
  Establ ished capsular penetrat ion: PCa extended into and poss ib ly through the 
prostat ic capsule  
  Seminal  vesic le involvement  
  LN involvement .  
PSA has been used as a marker s ince the 1990s, but despite i ts  remarkable 
performance, i t  becomes clear that i t  is  not an ideal cancer-specif ic  marker  (Jur inc ic 
et al .  1990) .  High PSA levels can a lso be observed in pat ients wi th benign prostate 
hyperplas ia (BPH) or  chronic inf lammation process es in the prostate. Spec ia l PCa 
subgroup cons is ts  of  pat ients with so cal led PSA-negative tumors.  In most of  cases 
these tumors are aggress ive inc luding bone metastases. Due to th is ,  some authors 
point out the necess i ty of  new PCa markers  and use the term “post -PSA era”.  I t  would 
be bet ter,  i f  s imple samples (e.g. b lood, ur ine)  could more accurate ly predic t disease 
progress ion. For example, i t  was reported in 2007 that a new blood test for  ear ly 
prostate cancer ant igen-2 (EPCA-2) may be able to predict PCa and i ts  
aggress iveness.  Research on this  st i l l  cont inues (Hansel et  a l .  2007, Margreiter  et a l.  
2008,  Bickers  and Auk im -Hast ie 2009) .  
Another subject of  studies has been the inf luence of  genet ic mutat ions on PCa course. 
The largest study that has invest igated the c l in ical character ist ics and outcome of 
pat ients wi th PCa with and wi thout  germ l ine BRCA mutat ions inc luded 1940 
noncarr iers and 79 BRCA carr iers (61 BRCA -2 and 18 BRCA-1) . Pathogenic mutat ions 
in BRCA-1 and BRCA-2 genes confers a more aggress ive PCa phenotype wi th a 
h igher probabil i t y of  local ly advanced and metastat ic  d isease and hypothes izes that  
the presence of  a germline BRCA-2 mutat ion is a prognost ic marke r assoc iated wi th  
poorer survival  (Castro et  al .  2013, Narod et  a l .  2008).  
Current ly,  there are many PCa treatment methods that have been developed and put 
into pract ice ; the main methods and “gold standards”  today are radiotherapy (RT) 
(brachytherapy or external  beam radiotherapy (ERBT)),  radical prostatectomy (RP) 
(open surgical :  retropubic  or per ineal,  and minimal ly invas ive: conventional 
laparoscopic  and robot-assis ted laparoscopic (Heer et a l.  2011) ) ,  as wel l  as 
ant iandrogen depr ivat ion therapy (ADT)  (Heidenreich et a l.  2012).  Many publ icat ions 
are devoted to the ef f ic iency of  only one these methods indiv idual ly,  i .e.  as  separate 
treatment  methods.  
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Radiation therapy.  
A large number  of  s tudies is devoted to RT.  RT of  ur inary tract  tumors and of  genita l 
organ tumors has a more than 100-year  h istory.  In  1895 , W . K.  Röntgen d iscovered 
the rays named af ter  h im. In 1899 , the f i rst  pat ient  was cured of  sk in cancer  by 
radiat ion, and in the next 10 years , radiat ion therapy began to be appl ied in PCa 
(Röntgen  1895,  Jantsch 1984).  
According to the general ly accepted hypothes is ,  ion izing radiat ion af fects tumor and 
normal cel ls ,  caus ing i r reparable damage to the double-s tranded DNA molecule. In 2/3 
of  the cases, this damage occurs due to oxygen-f ree radicals resul t ing f rom rupture of  
the covalent bond in the water molecule, and 1/3 of  the cases the ef fect is  d irect ly due 
to the ionizing radiat ion on DNA. Radiat ion damage occurs  only wi th the entry of  ce l ls  
into mitos is .  Moreover , there are data indicat ing that ionizing radiat ion st imulates 
apoptos is (Perez 1998).  
There are several types of  RT, which are d if fer ent iated by the way that ionizing 
energy is  adminis tered to the prostate .  
1.  Dose-escalated EBRT, the most modern var iety of  which is  3D -conformal RT.  
2.  External beam radiotherapy combined wi th a radioact ive seed implantat ion 
(EBSeeds) .  
3.  High-dose rate brachytherapy (HDR-BT).   
4.  Low-dose rate brachytherapy (LDR-BT).  
There are many studies on the ef f ic iency of  RT as a monomethod and on compar ing 
the ef f ic iency of  i ts  var ious types ( Pieters 2009). Thus, HDR-BT before EBRT with a 
reduced dose f rom the EBRT produces a comparable surv ival  outcome and 
genitour inary tox ic ity,  but s ignif icant ly less gastro intest inal tox ic i ty for  PCa pat ients 
(Fang et a l .  2008) . The 5-year b iochemical recurrence-f reedom (BCRF) rates for  EBRT 
+ HDR versus EBRT-alone were 67% versus 44% (Kest in et a l.  2000).  
The ef f ic iency of  RT in local ly advanced PCa could not be conf irmed -  the average 5-
year survival af ter  RT var ies between 45% and 86% according to d if ferent  sources 
(Fior ica et al .  2010, Kälkner et a l.  2007, Roach et a l.  1999) . However , the most 
s ignif icant  therapeut ic  factor af fect ing b iochemical recurrence -f ree survival  (BRFS) 
rates af ter  RT is  the radiat ion dose (Khunt ia et a l.  2004) .   
Our data based on 278 pat ients  wi th a 3 year  fo l low -up af ter  RT showed that BCR 
developed in 98 (35.2%) pat ients dur ing the f irs t  1.5 years af ter  RT. The BRFS in 
pat ients with cT2 and cT3 stage d if fers s ignif icant ly (75% and 44% respect ive ly) ;  
mean t ime to achieve BCR af ter RT was 2 and 1 year  respect ive ly (Ju enemann, 2004).  
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How should pat ients  wi th pos it ive surgical  margins  (PSM) to be treated? In these 
cases, the 3-year BRFS has been reported to be 73%-90% which is comparable to 
BRFS levels in pat ients with negat ive margins (Rabbani et a l.  2009). According to  the 
other studies, PSM increases the r isk  of  biochemical recurrence (BCR) af ter  RP by 2- 
to 4-fo lds (Stephenson et a l 2009).  But the other s ide of  the quest ion is –  when 
should RT be performed in the case of  PSM? 
In one of  the studies,  t he 7-year BCRF probabi l i t y was 60% in pat ients wi th PSM. A 
PSM was s ignif icant ly assoc iated wi th BCR (HR 2.3, p<0.001)  af ter  adjust ing for  age, 
PSA level,  pathological GS, pathological s tage and year  of  surgery.  Authors have 
pointed out that the empir ical  prognost ic  usefulness of  sub-c lassif icat ions of  PSM 
(sol i tary vs . mul t ip le,  focal  vs . ex tens ive and apical  locat ion vs . other)  is  l im ited 
(Stephenson et  a l.  2009).  
In a cohor t of  1943 pat ients who underwent RP , i t  was shown that PSM is s ignif icant ly 
predict ive for  PSA fa i lure  and thus the need for salvage therapy as wel l  as cancer -
spec if ic  survival (CSS) . The 5-year BRFS was 84.4% in men wi th negat ive margins 
compared to 57.5% with PSM (Ploussard et al .  2011) . The length of  PSM is 
s ignif icant ly assoc iated with d isease progression. GS and the extent of  PSM can be 
used to s trat i f y the r isk  for  recurrence in pat ie nts wi th a pos i t ive margin (Ochiai et a l .  
2008). The 5-year r isk  of  BCR was 20% resp. 55% for less than 3 mm resp. 3 mm or 
greater  (Chuang et a l.  2007) .  
The prostate weight was found to be s igni f icant ly and inversely re lated to the PSM 
rate in th is cohort of  RP pat ients . Pat ients wi th smal ler  prostate volume s (<50g)  
should be counseled preoperat ive ly that they are at  h igher r isk  for  a PSM wh en 
undergoing RP (Goetzl  et a l.  2009) .  
In  the case of  PSM af ter RP, RT can be used as a second (adj uvant)  treatment opt ion. 
50%-60% of  the pat ients wi th tumor stage pT 3R1  af ter  RP, who do not receive adjuvant 
therapy,  develop BCR. Three randomized t r ia ls have shown that an absolute 
improvement of  20% in the 5-year BRFS could be achieved by adminis ter ing adjuvant 
RT wi th 60 Gy in pat ients wi th tumor stage pT 3R1 ,  even i f  the PSA- level was c lose to 
zero af ter  RP. Also, there are numerous, a lbei t  retrospect ive studies, which provide 
evidence that salvage radiotherapy (sRT)  af ter  a PSA increase is an ef fec t ive 
treatment , but wi th h igher tota l doses of  66 -70 Gy and a h igher  rate of  la te ef fects 
(Bot tke and W iegel  2008) .  
Al l  the above-ment ioned resul ts show the necess i ty to  c lar i f y the indicat ions for  RT 
and adjuvant RT (Higano 2009). In case of  a pR1 stage , i t  is  necessary to perform 
radiat ion at least over a per iod of  6 weeks (W iegel et al .  2009).  The length of  the PSM 
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should be taken into cons iderat ion when def in ing the indicat ions for  sRT ( Chuang et 
a l.  2007) .  
sRT as a treatment opt ion for  recurrent PCa is a lso not devoid of  complicat ions. In a 
cohor t of  308 pat ients , la te tox ic ity occurr ing more than 90 days af ter  EBRT 
complet ion was ident i f ied in 13%. 12 (3.9%) of  the pat ients had grade 2 urethral  
str ic tures and were t reated wi th urethra l d i la t ion, 3 (1.0%) pat ients  suf fered f rom 
grade 3 cyst i t is ,  and one pat ient  f rom grade 4 recta l compl icat ions  (Peterson 2009). 
Another s tudy reports  that the average per ioperat ive compl icat ion level s of  sa lvage 
RT (both HDR-BT, EBRT and their  combinat ion)  was 9 .1% (Heidenreich et a l.  2010).   
The r isk  of  RT compl icat ions depends on the  tota l and s ingle focal dose. Meta-
analys is of  randomized dose escalat ion tr ials  demonstrates that la te  toxicity  rates 
increase with the RT dose (Ohr i et a l .  2012) .  In the case of  urogenita l t rac t tumors, 
the tota l focal dose should be no less than 65 Gy. In postoperat ive RT, doses of  45-50 
Gy are suf f ic ient (Spate and Roach 2000).  
One of  the latest studies on a cohor t of  1903 pat ients shows that the incidences of  
acute genitour inary and gastro intest inal  tox ic i t ies  were 35%, 49%, and 55% for 
brachytherapy a lone,  resp.  EBRT, resp. EBRT+HDR (p <0.001). Late genitour inary 
tox ic it ies were present in 22%, 21%, and 28% for brachytherapy alone, EBRT, and 
EBRT+HDR (p=0.01) ,  respect ive ly. Pat ients receiv ing EBRT+HDR  had a h igher 
incidence of  urethra l str ic ture and ur inary retent ion, whi le dysur ia was more common 
in pat ients receiv ing BT. Late gastro intest inal tox ic i t ies were 2%, 20%, and 9% for BT, 
EBRT, and EBRT+HDR respect ive ly (p<0.001).  Dif ferences were the most pronounced 
regarding rectal  bleeding, with 3 -year ra tes of  0.9%, 20%, and 6% (p<0.001) for  BT, 
EBRT, and EBRT+HDR respect ive ly (Mohammed et a l .  2012) .  
Most pat ients wi th PCa cT3 undergo neoadjuvant hormonal therapy fo l lowed by RT. 
The importance of  radiat ing both the prostate and the seminal vesic les  by us ing the 
new HDR-BT boost technique for cT3b PCa was pointed out in one of  the studies .  
Compared to radiat ion of  the prostate a lone,  th is type of  HDR-BT increases the 3-year  
BRFS f rom 57% to 79% and decreases the impotence rate f rom 35% to 24%, at  
comparat ive tox ic ity (Rades et  a l .  2007) .  
Radical prostatectomy.  
The r isk  of  PCa progress ion af ter  surg ical treatment depends on the degree of  
d if ferent iat ion, the morphological stage and the extent of  germinat ion of  the prostate 
capsule.  LN invas ion was a lso shown to be one of  the predic t ing factors.  The number 
of  removed LN plays an important ro le in the length of  the BCRF per iod, spec if ic  and 
overal l  survival  (OS) (Al laf  et  al .  2004, Bader et a l.  2003, Osmonov et a l.  201 3) .  
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Today,  the choice of  treatment tact ics takes into cons iderat ion the degree of 
d if ferent iat ion and stage of  the tumor, the pat ient 's  age,  the prognos is of  the long-
term re lapse-f ree per iod, the r isk  of  complicat ions, as well  as  the preferences of  the 
pat ient and the phys ic ian ’s  exper ience. Based upon these points , 3 groups of  pat ients 
are dis t inguished based on the r isk  of  BCR: low-r isk , in termediate-r isk  and h igh-r isk . 
The cr i ter ia by which these groups are d if ferent iated  (D’Amico et  a l  1993)  are as 
fol lows:  
 
Low risk  Intermediate risk  High risk  
PSA <10 ng/ml and GS <7 
and cT1–cT2a 
PSA 10–20 ng/ml or 
GS=7 or cT2b 
PSA >20 ng/ml or GS >7 
or cT2c–cT3 
 
We have analysed several large s tudies (wi th pat ient cohorts of  approx imately 1000 or 
more) to f ind out the comparat ive ef f ic iency of  pr imary PCa operat ive treatment vs.  
pr imary RT. To th is end,  we cons idered the 5-year BRFS level.  Results are showed in 
Table 1  (Par t in et a l.  1993, Catalona et a l.  1994, Z incke et a l .  1994, Paulson et al .  
1994, Kuban et a l.  1995, Z ietmann et a l.  1995, Khunt ia et a l .  2004, Sylvester et a l .  
2006, Bast ide et a l .  2006, Hernandez et a l .  2007, Yoshioka et a l.  2009, Burdick  et a l .  
2009, Loeb et a l .  2010).  The var iat ion in 5-year BRFS af ter RT is much h igher than in 
surgery.  The pr imary d if ferences l ie in the toxic i ty prof i les of  the treatments . 
General ly,  the BRFS, the c l in ica l recurrence-f ree survival (CRFS),  and the PCa CSM 
are near ly ident ica l  in  the pat ient  groups af ter  surgery and af ter  RT (Ciezk i  and Kle in 
2009).  
A fur ther  problem is hormone res is tant  PCa, based on a change in the androgen 
receptors . Lute inizing  hormone-re leas ing hormone (LHRH) inhib i tors , castrat ion and 
ant i-androgens are f requent ly combined into a total  androgen blockade or a combined 
androgen blockade (CAB), the most aggressive form of  hormonal  treatment used for 
advanced PCa. Al though i t  may take many years , hormone therapy wi l l  eventual ly fai l .  
The t ime of  fai lure is var iable -  some men (approx imately one in f ive) have recurrent  
growth with in a year f rom star t ing hormone t reatment ,  whereas others have no s ign of 
recurrent d isease af ter  10 years of  treatment  (W alsh 1997). The average t ime to PSA 
evidence of  regrowth ( i .  e.  hormone res is tance) is  2 .5 years (Buchan and Goldenberg 
2010).  One way to pro long BRFS is to g ive hormones in an on/of f -mode over several 
months. This is  cal led intermit tent  androgen depr ivat ion  therapy and some authors  
conc lude i t  as an acceptable treatment at  d if ferent stages of  PCa. The durat ion of  the 
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cyc le is decreased progress ively dur ing the therapy. Age, GS and PSA are factors 
predict ing morta l i t y (Prapotn ich et a l.  2009) .  
In advanced cases monotherapy of  PCa is of ten not ef fect ive and the d isease recurs : 
overal l  40% of  the pat ients have BCR with in  10 years of  fol low-up af ter  RP; however , 
the cancer-spec if ic  morta l i t y (CSM) rate af ter  10 years is as low as 6%  ( Isbarn et  a l . 
2010).  
I t  is  important to def ine,  what should be cons idered as a BCR, therefore requir ing 
ini t ia t ion of  sa lvage therapy.  Urologis ts  are usual ly guided by the level of  PSA and 
PSA-DT as impl ied by the term “b iochemical recurrence” .  In these cases, dynamic 
control  of  the PSA level  af ter  the operat ion is  absolutely required.  Clear ly 
standardized cr i t ica l levels of  PSA have  not yet been set down, but there is a 
tendency to reduce the current ly appl ied  level.   
In the stud ies by Heidenreich et a l .  (2009) and Parapel et a l.  (2008), the authors 
def ined disease progress ion by two consecutive PSA values of  >0.2 ng/ml.  The use of 
any adjuvant treatment (pr imar i ly ADT) was a lso considered to be a treatment fa i lure.  
Another study def ines BCR as a PSA level above 0 .5 ng/ml and/or a PSA-DT of  less 
than 10 months (Stephenson et  al .  2007) .  
Yet other authors suggest  that BCR is best def ined as two successive PSA levels > or 
= 0.4 ng/ml,  as th is correlates most accurate ly wi th c l in ica l progress ion. PSA -DT and 
GS are the var iables that best predic t the development of  dis tant metastas is and 
CSM. Prognost ic models based on these and other var iables are useful  for  assessing 
the need for salvage therapy and the ant ic ipated outcome fo l lowing local sa lvage  
therapy (Simmons et  a l.  2007).  
According to EAU Guidel ines 2014, there is in ternat ional consensu s that recurrent 
cancer fo l lowing RP may be def ined by two consecutive PSA values of  > 0.2 ng/ml 
(Moul  2000) .  
Regarding the terms of  fol low-up,  PSA measurements are recommended at the 
fol lowing intervals (according to EAU Guidel ines 2009  and to last EAU Gu idel ines 
2014): 3, 6 and 12 months postoperat ively,  and every 6 months thereaf ter for  the next  
3 years,  and then annual ly (Heidenreich et a l.  2009) .  
Treatment of  the d isease is the most compl icated  in pat ients  wi th recurrent PCa. What 
method of  treatment  should be of fered to the pat ient  in each individual  case? This 
quest ion cannot  be a lways answered wi th conf idence. Unfortunate ly,  the actual  choice 
is of ten inf luenced by the avai lable equipment, the phys ic ian ’s  exper ience and the 
«commitment» of  the c l in ic to a treatment pol icy (Kupel ian et a l.  1997, Kimura et a l.  
2010).   
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Salvage therapy.  
Salvage treatment of  PCa presents a  fur ther chapter in PCa management . That  
quest ion is current ly h ighly topical,  of ten caus ing controvers ial  d iscuss ions  on 
internat ional congresses. These d if f icu l t ies are due to the fac t that not many studies  
are devoted to salvage therapy for  recurrent PCa (Heidenreich et  a l .  2009,  2010, 
Leonardo et a l.  2009,  Parapel et a l .  2009,  Kimura et a l.  2010, Chade et a l.  2011, 
Rigat t i  et  a l ,  2011,  Suardi  et a l.  2011).   
There are only a few studies devoted to salvage radical prostatectomy (sRP) and 
salvage extended pelv ic lymph node d issect ion (SePLND). The volume of  such studies 
is much smal ler  than that on sRT because salvage surgery is not a s tandard 
procedure. Moreover , the number of  pat ients  inc luded in these studies is very smal l  in 
general .  The indicat ions for  th is type of  treatment, as wel l  as the pre-operat ive 
prognost ic r isk  factors  for  fur ther progress ion of  the d isease are not c lear ( Hautmann 
2006,  Paparel  et a l.  2009) .  
One of  the largest prospect ive analyses of  the SePLND impact on the prognosis o f  
pat ients with BCR and nodal pathologic 11  C-chol ine PET/CT scan af ter  RP inc ludes 
only 72 pat ients. 56.9% of  these pat ients  had a BCR. The 5-yr BCR-free survival  rate 
was 19%. Preoperat ive PSA <4 ng/ml,  t ime to BCR <24 months, and negat ive lymph 
nodes at  previous RP represented independent predictors of  BCR F. 5-yr CSS was 
75% (Rigatt i  e t  a l,  2011).  
The latest in ternat ional,  mul t i - ins t i tut ional cohor t analys is was performed on 404 men 
wi th radiat ion-recurrent PCa who underwent sRP between 1985 and 2009. There was 
a median fol low-up of  4.4 yrs fo l lowing sRP. Freedom from cl in ica l metastas is was 
observed in >75% of  pat ients 10 yrs af ter  surgery.  5 yrs af ter  sRP the rates were as 
fol lows: f ree f rom BCR: 48% (42-53), f ree f rom metastas is :  83% (78-87),  f ree f rom 
CSM: 92% (88-95). 10 yrs af ter  sRP the rates were:  f ree f rom BCR: 37% (31-43), f ree 
f rom BCR: 37% (31-43), f ree f rom metastas is :  77% (71-82) , f ree f rom CSM: 83% (76-
88)  (Chade et a l,  2010).  
sRP is  cons idered as a surgical ly chal lenging , but ef fect ive secondary local treatment 
of  radiorecurrent PCa with a curat ive intent  (Abdol lah et  a l  2012, Osmonov et a l.  
2013).  The ident i f ied predict ive parameters  wi l l  he lp to select pat ients most sui table 
for  sRP with a long- term cure and good funct ional outcome (Heidenreich et a l.  2010) .  
SePLND for selected pat ients wi th BCR and cl in ica l ly recurrent nodal  d isease on ADT 
can achieve an immediate complete PSA response in roughly one th ird of  the pat ients  
(Osmonov et a l.  2013) .  
The most appropr iate candidates for  sRP are pat ients wi th organ-conf ined d isease, 
BCR af ter pr imary RT  and s trongly wishing a therapy.  In exper ienced hands, morbid ity 
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af ter sRP is low wi th a cont inence rate of  83 %-96%. Long- term oncological control can 
be achieved in more than 80% of  the pat ients (Heidenreich et a l.  2008) .  
The compl icat ion rates of  salvage surgical  methods (SePLND and espec ia l ly sRP) 
have decreased as technical appl icat ions have improved cons iderably wi th in the last 
few years (d if ferent f ixed hold ing systems and t issue -coagulat ing systems) . Main 
compl icat ions are recta l injury (3 .6-6.0%), s tr ic ture of  b ladder  /  urethra l anastomos is 
(10.9-18.0%), ur inary incont inence (20-50%), and, very rare ly,  severe compl icat ions 
such as iat rogenic damage to the ureter or large b lood vessels (Hautmann 2006, 
Heidenreich et  a l .  2009).  
The EAU guidel ines recommend extended pelv ic lymph node d issect ion (ePLND) or 
sent inel-guided PLND (SgPLND) for LN staging in PCa. However, many authors point 
out,  that SgPLND of fers the advantage of  select ive removal of  sent inel  LN.  The 
addit ional expenditure and increased morbid ity of  ePLND has led to a l im i tat ion of  the 
PLND area and so to a reduced detect ion of  metastases in many c l in ics ( W inter et a l.  
2011).  
The Munich Cancer Registry study based on a cohort of  35629 men wi th  prostate 
cancer  has shown that RP should be performed in pat ients wi th pos i t ive LN, as LN-
pos i t ive  pat ients  with complete RP had improved  survival  rates compared to  pat ients  
with abandoned RP. Thus, the overal l  survival (OS) of  pat ients  wi th RP at the 5 yr -  
and the 10 yr - in terval was 84% and 64% respect ive ly;  but only 60% and 28% 
respect ive ly, in pat ien ts wi th abor ted RP. The re lat ive survival of  pat ients  wi th RP at 
the 5 yr  and 10 yr interval was 95% and 86% respect ive ly; and 70% and 40% 
respect ive ly,  wi th abandoned surgery  (Engel  et a l.  2010) .  
In our previous study i t  was shown that LN metastases were detected in 15 of  106 
pat ients (14.15%) dur ing RP. Posi t ive sent inel LNs were detected in 11 of  these 15 
pat ients (73.3%).  The average number of  removed LN was 20.5 (range + /-5).  I t  was 
shown that rout ine use of  ePLND leads to increase d detect ion of  h isto logical ly 
pos i t ive LN, whi le the number of  compl icat ions is not increased (Osmonov et al .  
2011).  
There are controvers ia l opin ions that the data avai lable to date do not just i f y the use 
of  SePLND outs ide c l inica l tr ia ls due to the smal l  number of  p at ients inc luded, the 
lack of  contro l groups as well  as the short - term fo l low-up (Suardi et  a l .  2011).  We 
bel ieve however , that  the standard technique of  ePLND needs to be revised and 
supplemented by addit ional d issect ion areas such as the tr iangle of  Marc i l le,  the 
sacral  LN,  and the preprostat ic area (Osmonov et  al .  2011) .  
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The technique of  RP is wel l -known, and a l l  s teps of  this  operat ion have a lready been 
standardized (Rasswei ler  et a l.  2006, Sto lzenburg et a l.  2008,  W alsh 1988). The 
technique of  ePLND by contrast,  is  ext remely dependent on the inst i tu t ion and the 
surgeon’s exper ience (Br igant i  e t a l.  2008) .  In our ear l ier  studies,  we have 
recommended standardizing ePLND and suggested a pract ica l  guidel ine for  surgeons 
(Osmonov et a l.  2011,  2013) .  
Diagnost ics  of  nodal  metastases has been s ignif icant ly improved ; 11C-chol ine- 
pos i tron emiss ion tomography /compute r ized tomography (PET/CT)  play the main 
ro les  in  BCR management.  The d iagnost ic  accuracy of  chol ine PET in detect ing the 
s ites of  PCa re lapse has been invest igated by several authors, and the overal l  
repor ted sens it iv i t y ranges between 38% and 98%. I t  has been demonstrated that the 
chol ine PET pos i t ive detect ion rate improves wi th increas ing PSA values. The rout ine 
use of  11C-chol ine PET/CT cannot be recommended for PSA values <1 ng/ml (Picchio 
et  a l .  2011) .  
Our own recent data show that the re l iabi l i t y of  11C-chol ine PET/CT imaging for 
detect ion of  LN metastases is l im ited by a h igh fa lse -pos i t ive rate. Spec if ic i t y and 
sens i t ivi t y of  11C-choline PET/CT in detect ing of  LN metastases appeared to be 
22.7% and 85.1% respect ive ly (Osmonov et a l.  2013) .  
Besides general surgical compl icat ions there are a lso spec if ic  potent ia l  compl icat ions 
assoc iated wi th ePLND. These include lymphoceles , which make up 10.6% of  a l l  
compl icat ions af ter  ePLND ( in compar ison, l im ited PLND ( lPLND) has a 9% 
lymphocele rate) .  Another poss ib le complicat ion is lymphedema of  the lower  
extremit ies,  but  for tunate ly th is  occurs  only rarely (Heidenreich et  a l.  2002) .  
The def in i t ion of  ePLND is d isputable. How many LN should be removed dur ing 
pr imary RP? Our recent data based on 174 pat ients wi th in termediate and h igh -r isk  
prostate cancer  show that  at least 15 LN in the intermediate r isk  group and at least 18 
LN in h igh r isk  group should be removed to detect  the a maximum number of 
metastases . I f  fewer LN are removed, the probabi l i t y of  non -detected metastases 
increases. In intermediate r isk  pat ients (n=115) the average number of  LN removed  
was 20.5; LN metastases were found in 15 pat ients (13%) . In high-r isk  pat ients (n=59)  
the average number of  LN removed was 23.9, LN metastases were found in 19 
pat ients (32%)  (Osmonov et  a l .  2013).  
SePLND s ignif icance in case of  BCR wi l l  be shown in the course of  th is study.  
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Issues addressed by the study:  
1.  How can the surgical  method be opt imized in pat ients wi th advanced PCa?  
2.  What is  to be done in case of  BCR? Is  sRP a val id  treatment  opt ion af ter  RT? 
3.  What is  the ro le of  ePLND, espec ia l ly in  pat ients wi th recurrent d isease ? 
4.  In how far  does the number of  removed LNs corre late wi th BRFS and cancer-
spec if ic  survival  (CSS)? 
5.  How can the s i te/ro le  of  pre- and postoperat ive RT in pat ients wi th recurrent  
PCa be best  ident i f ied?  
6.  When is  the best  t ime to in i t ia te ADT af ter  pr imary treatment?  
7.  What is  the inf luence of  ADT on BCRF?  
8. What is  the f requency and re levance of  salvage - therapy compl icat ions?  
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PATIENTS  AND  METHODS 
 
Study population and data 
In our s tudy we represent the s ingle-center  retrospect ive analys is of  surg ical sa lvage 
procedures (SePLND and sRP) in pat ients wi th PCa recurrence. A cohort of  41 
pat ients f rom our department  has been inc luded in our  study.   
Inc lus ion cr i ter ia :  
  His tological  proof  of  PCa.  
  BCR and/or suspic ious ly low PSA-DT.  
  Salvage therapy of  PCa (sRP, SePLND, sRT or combinat ions thereof) .  
  Absence of  bone metastases at the t ime of  salvage therapy.  
 
There is  st i l l  no def in it ion of  PCa re lapse or progress ion.  We def ined PCa progress ion 
as a PSA cut-of f  of  ≥0.5 ng/ml and/or PSA-DT <6 months.  So, we cons idered progress 
of  the d isease as a BCR. We descr ibed the s i tuat ion as a b iochemical response (BR) , 
i f  af ter  salvage operat ion PSA level  was below the preoperat ive level and cont inued to 
fal l ,  even i t  was above BCRF cr i t er ia . Tak ing into cons iderat ion the var iable sequence 
of  d if ferent treatment  methods, we formed several  groups,  which wi l l  be d iscussed 
below.  
To evaluate the ef f ic iency of  treatment we took into accoun t the fol lowing indicators:  
a)  the pat ients ’ age  
b)  the degree of  tumor d i f ferent iat ion by GS 
c) the r isk  strat i f icat ion according to D’Amico c lass if icat ion  
d)  the in it ia l  PSA ( iPSA) at  the t ime of  pr imary treatment  
e)  the s tage of  the d isease according to  TNM-c lassif icat ion ( inc luding the R stage)  
f )  the PSA-DT, both before and af ter  salvage therapy in re lat ion wi th  
presence/absence of  ADT  
g)  durat ion of  the BCRF-per iod 
h)  CSS 
i)  local izat ion and number of  metastases in removed LN  
j )  the type and dose of  RT 
k) the presence/absence of  d is tant metastases  
l)  compl icat ions connected wi th sRP and SePLND 
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The Results  sect ion has been s tructured on the bas is of  the above - l is ted parameters.   
Among 41 pat ients included in the study,  40 pr imari ly or secondary underwent RP. 
This operat ion was the pr imary method of  treatment in 30 (73.2%) pat ients , whereas  
in 10 (24.4%) pat ients i t  was secondary t reatment opt ion (sRP). In one pat ient i t  
turned out in traoperat ive that preparat ion of  the prostate was imposs ib le due to 
changed t issue propert ies ( f rozen pelv is)  af ter  pr imary RT, therefore only SePLND 
was performed.   
In  Group 1 (sRP) surgery of  the prostate  inc luded ePLND in a l l  cases. In group 
pr imary RP just  19 (63.3%) RPs were supported by ePLND.  66.7% of  the pr imary RPs 
had been performed in external departments .  
Al l  pr imary and salvage prostatectomies perfor med at our depar tment were done 
according to the c lassic technique of  RP (Walsh 1988) . Access was  retropubic,  the 
operat ion t ime was 180 minutes on average and the average blood loss was 300 ml. In  
those pat ients wi th in tact  erect i le funct ion ,  the pr imary RP is  usually performed wi th 
b i la tera l preserve of  the neurovascular bundle, in contrast to  sRP. Anastomosis is  
formed by s ix sutures. The obl igatory f rozen sect ion  pract ice is  performed in a l l  
pat ients immediate ly af ter  the prostate has been removed. I f  necessary, PSM 
resect ion is  performed.  In most  cases (63.3%),  pr imary RP was supplemented by 
regional  PLND on both s ides.  
 
Diagnostic methods 
W e imaged the prostat ic gland and the tumor -suspect areas in the per ipheral zone of  
the prostate by means of  preoperat ive power  doppler transrecta l u l trasonography (PW 
TRUS; Nemio XG Premium, model SSA-580A, Toshiba, Japan)  pr ior  to pr imary RP.  We 
compared these f indings wi th the his tological  b iopsy repor t.  Subsequent ly,  we injec ted 
the radioact ive marker Tc -99 into the per ipheral zone into both prostate lobes to 
enable in traoperat ive usage of  C-Trak gamma probe (AEA Technologies,  Morgan Hi l ls ,  
CA, USA) for  sent inel LN detect ion. The method cons ists of  in traoperat ive scanning of  
the lymphat ic pathways to ident i f y the locat ion of  the sent inel LN groups in the depth 
of  the wound, as wel l  as to remove paravasal and pelv ic LN t issue. An increase of  the 
index up to more than 20 cps (counts per second) indicates excessive accumulat ion of  
Tc-99 in the scanned area. Thus, probabil i ty of  metastas is is  h igher  in th is area;  th is 
a lso helps to improve intraoperat ive or ientat ion at the stage of  ePLND and increases 
the probabi l i t y of  h isto logical tumor cel l  detect ion in the removed LNs. Sc int igramms 
are performed pr ior  to surgery,  which provide the oppor tuni ty to  v isual ize  increased 
accumulat ion of  the radio isotope drug. On scint igramms or sent inel scan a sharply 
intens if ied s ignal  f rom the prostate i tse lf  is  a lways seen.  
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Figures 2 and 3  present  the 11C-choline PET/CT and sc int igramm resp. ,  which show 
sent inel  LNs on the lef t  s ide, in addi t ion to the increased accumulat ion of  radio isotope 
drug in  the prostate.  
When BCR was diagnosed, we performed an 11C-chol ine PET/CT (Siemens, 
Germany) . I f  the regional LNs were suspect for  metastases in  11C-chol ine PET/CT 
af ter  pr imary treatment fa i lure,  SePLND was indicated. This d iagnost ic method has a 
re lat ive ly h igh sens iv i ty,  as  chol ine is  accumulated main ly by tumor t issue and is 
a lmost absent  in  normal LN t issue.  
Al l  the pat ients inc luded in the s tudy underwent bone scint igraphy to exc lude d istant  
metastases in the skeleton. Pat ients  wi th evidence of  bone metastases were exc luded 
f rom the s tudy.  In spite of  this ,  4 (9.8%) pat ients were found to have bone metastases 
dur ing the fo l low-up. Al l  of  them received Zometa and were under  complete androgen 
b lockade.   
 
Surgical technique 
Regardless of  whether PLND was inc luded in the RP, or whether i t  was an 
independent method of  salvage therapy, there was a standard approach for LN 
removal,  schemat ical ly presented in Figure 4 .  We dist inguished the fo l lowing groups 
of  regional LNs for  the prostate (Osmonov et  a l .  2011):  
  LN dissect ion (LND) in the fossa obturator ia;  
  Sacral  LND;  
  LND in the region of  external  i l iac  ar tery;  
  LND in the region of  in ternal  i l iac  ar tery;  
  LND in the region of  common i l iac  artery;  
  LND dissect ion in presciat ic area or the “ tr iangle Marc i l le” .  
 
Technical features of  ePLND and detai ls  of  LN dif ferent iat ion on above -ment ioned 
groups were well -descr ibed in a recent publ icat ion f rom our inst i tu t ion (Osmonov et a l.  
2011). W e performed SePLND as fo l lows:  choos ing a transper itoneal access, we 
def ined landmarks such as the i l iac vessels before beginning with the d issect ion. The 
ureter was ident i f ied and separated carefu l ly f rom the surrounding t issue. L N 
dissect ion was then performed systemat ical ly f rom top downwards. Small  or  medium 
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cl ips were used to avoid extens ive l igat ion.  We used the Harmonic Scalpel® (Eth icon 
Endosurgery,  USA) to seal  the LN vessels  and to shorten the operat ion t ime. Standard 
operat ing rout ine inc ludes the fo l lowing (F igure 4) :   
1.  The pat ient was in the supine pos it ion and rotated to the s ide of  LN dissect ion. 
The wound was exposed in the region of  the fossa obturator ia by means of  a Book -
Walter retractor.  
2.  Margins of  the LN dissect ion in the fossa obturator ia: the upper margin is the 
top edge of  the external i l iac vein, the lower  margin is the obturator nerve; the angle 
between the lower edge of  the external i l iac vein and the pubic bone is crania l ,  and 
the b ifurcat ion of  the common i l iac  artery is  caudal.  
3.  The upper margin of  sacral  LN dissect ion is the obturator nerve, the lower 
margin is the latera l edge of  the neurovascular bundle (NVB) of  the prostate, the 
crania l margin is  the foramina obturator ia, and the caudal margin is the ure ter.  
4.  LN dissect ion in the so-cal led presc iat ic area inc ludes the last one-th ird of  the 
backside area of  the external i l iac vein c lose to the b ifurcat ion of  the common i l iac 
vein.  
5.  LN dissect ion along the common i l iac artery is performed as fo l lows:  Dissect ion 
and c l ipping is done in the same way in the caudal d irec t ion, wi th a carefu l stump 
separat ion of  the LN down f rom the pelvic  wal l  us ing a min i -swab. W e recommend 
pul l ing the external  i l iac artery to latera l af ter  reaching three -quarters of  the 
d issect ion length, to c lear the surface of  the common i l iac vein. W e recommend 
removal of  LN t issue of  at least 3 cm along the common i l iac artery or up to the ureter 
cross ing point (Osmonov et  al .  2011) .  
The d issect ion areas of  SePLND were as fo l lows: 1. LND paraa orta l,  2 LND 
inter i l iacal,  area between the r ight and lef t  common i l iac  ar tery,  3. LND in the region 
of  the common i l iac ar tery on the both s ides,  4. LND around the promontor ium, 5. LND 
in the presc iat ic area or the “ tr iangle Marc i l le” ,  6. LND in the regio n of  the internal  
i l iac  ar tery, 7. LND in the fossa obturator ia.  8. LND in the region of  the external i l iac 
artery.  9.  LND in the sacral  area (F igure 4) .  
Addi t ional ly we a lso at tempted to standardize SePLND in view of  the operat ive 
l im itat ions of  salvage surgery due to the scar format ion af ter  pr imary therapy and the 
presence of  eas i ly damageable s tructures l ike pelv ic  vessels and nerves.  
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Dividing into groups 
W e included 41 pat ients in th is study, who underwent a var ious combinat ions of  
sa lvage treatment of  their  PCa-BCR pr ior  to salvage surgery between November 1997 
and June 2011.  We formed 3 groups of  pat ients  according to the type and combinat ion 
of  salvage therapy opt ions being performed for subsequent analysis.  The common in 
a l l  three groups was SePLND as the only salvage treatment or as a par t of  i t .  
Schemat ic  sequence of  treatment  opt ions in each group is shown in Figure 5 .  
Group 1  (n=10) cons ists of  pat ients  wi th pr imary RT and subsequent salvage RP with 
ePLND. Median fo l low-up af ter  the sRP was 40 .0 ± 11 .2  months (24-59 months) .  
Group 2 (n=22)  cons is ts of  pat ients  wi th pr imary RP and subsequent SePLND. Median 
fol low-up af ter  SePLND was 32.3 ± 27 .0 months (1 -  90 months) .  
Group 3  (n=9)  cons ists of  pat ients  wi th pr imary RP and subsequent sRT. Median 
fol low-up af ter  sRT was 60.2 ± 24 .5 months (24 -  112 months)  (Figure 5,  Table 2 ) .  
Across the groups RT was performed in  33 (80.5%) pat ients . In 10 of  them RT was the 
pr imary treatment for  PCa  and in 23 pat ients RT was performed as salvage treatment.   
We also analysed the inf luence of  ADT on the fol low-up. Thir ty (73.2%) f rom the tota l  
of  41 pat ients received ADT at  some stage of  their  treatment.  Tak ing into 
cons iderat ion that a l l  pat ients had a BCR pr ior  to salva ge surgery and 25 (61.0%) 
received an ADT pr ior  to salvage surgery;  these 25 (61.0%) pat ients  had a hormone 
res istant PCa at the t ime of  salvage surgery. T erms of  ADT and correlat ion wi th other  
treatment  methods were analysed.  
W e would l ike to point out that 27 of  41 pat ients, received one or more secondary 
salvage treatments  (out of  these there were 22 secondary SePLND, 3 secondary 
cases of  salvage RT, 3 secondary cases of  salvage adjuvant RT and one secondary 
salvage RP). For example,  3 pat ients f rom Group 2 underwent SePLND twice and one 
pat ient even three t imes. Two pat ients in  the same group underwent adjuvant RT 
(short ly af ter  the SePLND) and 3  fur ther  pat ients underwent sRT as a secondary 
salvage treatment . St i l l  in th is  same group,  7 SePLNDs were cons idered as secondary 
salvage opt ions as they fo l low the adjuvant  RT. In Group 3 e ight  pat ients underwent 
SePLND and one pat ient  sRP as secondary salvage treatments. In Group 1 one 
pat ient received sRP as a second salvage t reatment .  
Our goal  is  to analyse the overal l  resul ts of  sa lvage therapy,  therefore we  wi l l  not 
d ist inguish between pr imary and secondary salvage treatments in the fo l lowing 
analys is .  Thus, we present only the above-ment ioned three groups of  pat ients  
(Diagram 1 ) .  BCRF, CSS and the inf luence of  ADT were analysed according to the 
goals of  our study.  
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RESULTS 
The resul ts are s tructured according to the previous ly ment ioned goals  of  the study.   
a)  Patient age:  The d is tr ibut ion of  the pat ient age is presented in Table 2 .  Group 
1 conta ined the  o ldest pat ients  on average, the lowest average age was found in 
Group 2. Overal l ,  the average age of  the pat ients at the t ime of  pr imary treatment was 
62.3 ±  8.7 years  (49 -74 years) ;  at the point of  salvage treatment i t  was 66.1 ± 6.5 
years  (54-78 years).  
b)  Degree of tumor different iation: Distr ibut ion of  the pat ients by Gleason Score 
(Diagram 2) showed that the dominant score was 7 (43.9% of  pat ients) ,  then score 9 
(22.0%), score 8 (17.1%), score 6 (9.8%), score 10 (2 .4%). In two pat ients (4.9%) in, 
the GS could not  be determined accord ing to the h isto logical  analys is .  Relying on th is 
indicator ,  i t  can be said that the percentage of  pat ients wi th low-r isk  was no more than 
9.8%, pat ients  with intermediate - and high- r isk  c lear ly dominated. This is  not  
coinc identa l ,  as a l l  pat ients inc luded in the study sooner or later had a PCa 
recurrence. This can a lso be seen as fur ther proof  of  the re levance of  the GS in BRFS 
prognosis .  
c)  Risk strat if ication:  According to the D’Amico r isk  c lass if icat ion ,  there were 3 
(7.5%) pat ients  wi th low-r isk , 13 (32.5%) pat ients wi th in termediate  r isk  and 24 
pat ients (60.0%) wi th h igh-r isk  prostate cancer . In one pat ient  f rom Group 1,  i t  was 
imposs ible to determine the r isk  category.  In Group 1, h igh-r isk  pat ients  (77.8%) 
predominated, wi th only two intermediate- r isk  pat ients . The r isk  distr ibut ion ( low-
intermediate-h igh) in Group 2 was 2 –  6 -  14 (resp. 9.1% - 27.3% - 63.6%); in Group 3 
i t  was 1 -5 -  3 ( resp.  11.1% - 55.6% - 33.3%) . The clear  predominance of  high-r isk 
pat ients in Groups 1 and 2 and of  in termediate- r isk  pat ients  in Group 3 has been 
analysed (Diagram 3) .  
d)  Init ial PSA values:  The iPSA level was a lso d if ferent in  the three pat ient  
groups (Diagram 4).  In Group 1,  i t  was 33.2 ng/ml,  in  Group 2 –  19.0 ng/ml,  in Group 
3 –  12.1 ng/ml.  The prevalence of  a h igh iPSA level in Group 1 could be seen as 
predict ing potent ia l ly less favourable postoperat ive resul ts.  This  hypothes is wi l l  be 
proved or  d isproved in fo l lowing analys is .   
e)  TNM-classif icat ion:  I t  has been ment ioned above that the s tage of  the d isease 
by TNM c lass if icat ion is also impor tant  in  predic t ing the r isk  of  PCa recurrence. 
Among the studied pat ients , stage cT1 was not ident i f ied. Stage cT2 was d iagnosed in 
17 (42.5%) pat ients ; regarding the d is tr ibut ion of  cT2a -  cT2b -  cT2c, the lat ter  was 
dominat ing wi th 3 -  5 -  9 pat ients  respect ive ly. Stage cT3 was d iagnosed in 21 
(52.5%) pat ients wi th cT3a and cT3b found a lmost equal ly in 10 resp. 11 pat ients. In 2 
pat ients i t  was not  possible to def ine the s tage by the TNM c lass if icat ion.  
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f )  PSA-DT and ADT:  We cons idered the PSA-DT as the pr imary index of 
treatment ef f ic iency.  Based upon PSA levels, we analysed the PSA-DT in a l l  three 
groups of  pat ients . Fi rst  we calculated the  PSA-DT before salvage treatment .  As 
mentioned above, a l l  of  pat ients who received ADT before salvage surgery (n=25;  
61.0%) had BCF and therefore were hormone res istant at the t ime of  salvage surgery.  
W e also attempted to take into cons iderat ion the inf luence of  ADT on the PSA-DT 
level  (Diagram 5 ) .  
In Group 1, the mean level of  PSA-DT pr ior  to sRP was 13.8 months (without ADT) 
and 12.3 months (with ADT). Fur thermore,  2 pat ients showed a PSA regress af ter  ADT 
was prescr ibed, but the PSA level remained ≥0.5 ng/ml.  In 5 pat ients (50%) we 
observed a BCR-free per iod f rom 16 to 75 months (mean BCRF per iod in th is group 
was 34 months)  (Diagram 5 ) .   
In Group 2, the mean level of  PSA-DT pr ior  to SePLND was 9.2 months (without ADT) 
and 11.3 months (wi th ADT). In 11 pat ients (50%) we observed  a BCR-free per iod of 
10 to 92 months (mean BCRF per iod in th is  group was 40.6 months)  (Diagram 5 ) .  
In Group 3, the mean level of  PSA-DT pr ior  to  sRT was 18.1 months (wi thout ADT). 
Just one pat ient in th i s group underwent  ADT, his  PSA-DT was 4 months. In 3 pat ients 
(33.3%) we observed BCR-free per iod f rom 32 to 72 months (mean BCRF per iod in 
th is  group was 50.3 months)  (Diagram 5 ) .  
Moreover,  we analysed the PSA-DT in a l l  groups after the f irst salvage treatment  
(salvage surgery in Group 1 + 2, sRT in Group 3)  (Diagram 5 ) .   
In Group 1 four pat ients (40%) needed to receive hormonal therapy af ter  salvage sRP.  
In th is group, 6 of  10 (60%) pat ients had a BCRF per iod of  6 to 43 months ( the mean 
BCRF per iod in th is group was 27.2 months),  3 pat ients  (30%) cont inue to be BCR-
free at  the t ime of  analys is (35, 27, 43 months).  The average durat ion of  PSA-DT af ter 
sRP without appl icat ion of  ADT treatment was 4.5 months. From the t ime that  ADT 
was in it iated, one pat ient had a BCRF of  43 months and the level of  PSA cont inues to 
remain below 0.5 ng/ml.  In a fur ther  pat ient the PSA level –  a l though not meet ing 
BCRF cr i ter ia -  showed a s ignif icant regress by 78% af ter ADT  in it iat ion. Another 
pat ient achieved a PSA-DT of  7 months with ADT. Only one pat ient developed bone 
metastases 2 years af ter  sRP (Diagram 5 ) .  
As ment ioned before,  SePLND was performed twice resp. three t imes in 3 pts.  resp. 
one pat ient.  Therefore,  we evaluated the results of  27 SePLN Ds in th is group. In i t ia l ly 
no ADT was prescr ibed postoperat ively,  but then 11 out of  24 (40.7%) pat ients had to 
undergo hormonal t reatment.  Overal l ,  the resul ts in  Group 2 were favourable –  63% 
pat ients had a BCR-free per iod of  2 to 60 months (mean BCRF per iod in this group 
was 17.5 months) .  The remain ing three pat ients a of  PSA regress which remained 
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above BCRF cr i ter ia . I t  is  impor tant to mention  that  in 5 out of  17 (29.4%) pat ients 
BCRF continued at the t ime of  analys is ( for  2,  3,  3,  5,  12 months).  The major i ty of 
these pat ients underwent salvage surgery in  2011; therefore their  BCRF fo l low-up was 
only 2-5 months so far .  
The mean level of  PSA-DT af ter  SePLND without  appl icat ion of  ADT treatment was 6.1 
months; in pat ients who received ADT  the PSA-DT was 9.0 months. Af ter ADT was 
ini t ia ted, three pat ients had BCRF and the other two pat ients had a  regress of  PSA 
level ,  but remained over BCRF cr i ter ia for  15 and 30 months.  
In 3 pat ients f rom Group 2 secondary sRT was performed af ter  SePLND, and we 
dec ided to fur ther analyse to these 3 cases.  I t  appears that a l l  of  them sooner or later  
received ADT t reatment , and a l l  of  them had a BCRF-per iod of  35 to 45 months (mean 
per iod was 40.7 months).  One of  these pat ients unfor tunate ly d ied of  pancreas 
cancer , despi te of  good PCa contro l .   
In Group 3, four  pat ients (44.4%) needed to receive hormonal therapy.  W ith ADT, 3  of  
the 9 pat ients (33.3%) had a BCR-free per iod of  12 to 26 months (average BCRF was 
17.6 months) ,  thus 2 pat ients (22.2%) have cont inued BCR-free at  the t ime of  analys is  
(15 and 26 months).  In a l l  of  them , BCRF started af ter  ADT therapy was in it iated. The 
average PSA-DT af ter  sRT without ADT treatment was 12.6 months. Three pat ients 
(33.3%), who did  not  receive ADT treatment , showed a regress of  the PSA level,  
which remained over  BCRF cr i ter ia, but decreased by 1.6 t imes on average in 
compared wi th the PSA level  before sRT .  
When calculat ing the PSA-DT, we combined Groups 2 and 3 because SePLND was 
performed as a f inal  sa lvage treatment  in  both these groups  (Diagram 5 ) .  
g)  BCRF survival:  In  tota l,  BCR-freedom was observed in 23 of  41 pat ients  
(56.1%) af ter  salvage surgery.  As many as 75.6% of  a l l  pat ients showed a BR, i .e. a 
decrease of  the PSA- level .  W e summarized a l l  obta ined results af ter  salvage 
treatment  in  Tables 3,  4 .  
We also performed s tat is t ica l  analysis  of  a l l  three groups in tota l (n=41) .  The average 
BCRF-survival  was 21.4 months (95% CI 16.768 –  26.024;  Std.  er ror 2.361).   
h)  Cancer-specif ic survival:  CSS analys is was a lso performed for al l  three 
groups. W e inc luded in CSS analys is only those pat ients , whose fol low-up was more 
than 24 months (n=23). The resul ts were as fol lows: 95% conf idence interval of  5-
years  CSS = 66.97%-100%; Hazard-Rat io = 0.006683 (95% CI = 0 –  0.006683) ; 
median CSS = 103.7 months.  I t  is  stat ist ica l ly ir rat ional to calculate CSS for each 
group because the small  number of  pat ients  inc luded in the s tudy. The smal l  number 
of  pat ients  a lso causes the wide margins of  the 95% conf idence interval.  
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i )  Number and local isat ion of metastases in removed LNs:  W e have calculated 
the number of  removed LN in al l  SePLNDs and combined sRP+SePLND, addit ional ly 
tak ing into cons iderat ion their  local izat ion. In each group of  LN the number of 
metastases was determined.  These data are shown in Diagram 6 .  
The f requency of  f inding LNs and a share of  metastases among them  were calculated 
for  each group. These data are presented in Diagram 7 .   
In tota l,  N1 stage was establ ished af ter  13.3% RP operat ions, af ter  30.0% sRP 
operat ions and af ter  58.3% SePLND –operat ions (Diagram 8) .  
W e found the number  of  detected LN metastases to be ca. 5.6 t imes h igher af ter  
salvage surgery than af ter  pr imary RP (14.8% and 2.65% respect ive ly) .  Thus the 
f requency of  f ind ing metastases in removed LNs dur ing sRP is comparable wi th 
SePLND (15.0% and 14.7% respect ively)  (Diagram 9, 10) .  I t  has turned out that  most 
metastases dur ing salvage surgery were found in the a. i l iaca communis LNs and the 
presacral is  LNs ( tota l 17.9% and 15.4% respect ive ly) ,  fo l lowed by LNs f rom the region 
of  the a. i l iaca externa (12.2%), a. i l iaca interna (12.1%), and the Marci l le tr iangle 
(10.0%). The least f requent detect ion of  metastases was in the obturator LNs (4.3%).  
Although a re lat ive ly large number of  nodes (116) was  removed f rom this area –  which 
is standard in lLND-, the percentage of  LN metastases is very low. More LNs were 
only removed in the a.  i l iaca communis area (190) and the a. i l iaca externa (172), but 
there the percentage of  pos i t ive LNs was as h igh as 17.9 % resp. 12.2%.  
Actual ly the most f requent  metastases by far  were found in the group  “Other LNs”  
(27/84, or 32.1%) –  th is group juts out because i t  main ly inc ludes LNs that were not 
re lated to the regional  LNs -  most ly paraaor ta l,  paracaval and interaor toca val - ,  which 
had previous ly been ident i f ied as d is tant metastases in the preoperat ive PET-CT. The 
number of  removed LNs and the f requency of  metastases per LN group when 
compar ing the Groups 1 and 2 were a lmost equal.  
In SePLND (Groups 2+3) 16.6 (2-36) LNs were removed per pat ient ,  and 14.7% of  
these were pos i t ive. In sRP (Group 1) as many as  18.0 (9-26) LNs were removed per 
pat ient and 15.0% of  these harboured metastases. In contrast,  only 7.8 (0-36) LNs 
were removed per pat ient dur ing pr imary RP, and only 2.65% of  these were pos i t ive . 
When compar ing pr imary RP (wi th lLND) and SePLND, i t  becomes clear that  both the 
number of  removed LNs and the percentage of  pos i t ive LNs found is much h igher in 
SePLND. (Diagram 11 ) .  
j )  Type and dose of RT:  33 RT treatments were performed in 41 (80.5%) 
pat ients. Among these, 14 were performed in Group 2: as adjuvant RT af ter  pr imary 
RP (8),  as adjuvant RT af ter  SePLND (2) ,  as sRT af ter  SePLND (3),  and as a pr imary 
treatment opt ion (1) .  Diagram 12  shows the dis tr ibut ion by RT t ype, wi th a prevalence 
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of  external RT (66.7%). This fac t may indirect ly point towards a greater  r isk  of  late 
postoperat ive compl icat ions. The radiat ion doses for  each pat ient are also known.  
k ) Distant metastases:  As ment ioned above, d istant metastases were found by 
bone scint igraphy in four pat ients dur ing the post -salvage fo l low-up per iod. Al l  of  them 
received ADT and Zometa. In one pat ient ,  however , abnormal accumulat ion of  the 
radiopharmaceut ica l drug was observed in the pelvic LNs, and therefore the RP 
included the removal  of  dis tant LN f rom paraaorta l region in addit ion to regional  
ePLND. As a result ,  8  out of  8 removed paraaor ta l LNs were found to be pos it ive for  
metastases (100%). In the same pat ient ,  5 LN metastases were found in the 18 
regional  LNs (27.8%),  so the rat io  of  pos it ive LNs was a lmost twice as h igh as the 
average rat io (14.8%). 28 months af ter  the operat ion  the level of  PSA, which had 
previous ly been >100 ng/ml,  dropped down to 37.7 ng/ml.  Af ter  ADT ini t ia t ion, the 
level of  PSA dropped to 1.6 ng/ml,  then s lowly rose to the current  level of  6.9 ng/ml.  
In the fur ther course bone metastases were diagnosed, and the pat ient addit ional ly 
received Zometa. The second pat ient wi th bone metastases had a PSA level of  5.5 
ng/ml at the t ime of  analys is . The last two pat ients wi th d istant metastases had PSA 
levels of  59.4 resp. >100 ng/ml despite t reatment  with chemotherapy (Docetaxel) .  
These pat ients  require fur ther observat ion.  
l)  Complication rate:  We have a lso analysed a l l  complicat ions that  occurred 
intra-  and postoperat ive ly. In the fo l lowing they wi l l  be only l is ted, but there wi l l  be a  
detai led d iscuss ion of  compl icat ions in the chapter  below (Table 5) .  
Two of  the 41 pat ients (4 .9%) inc luded in the study,  underwent re- laparotomy was 
performed (2
n d
 resp.  3
r d
 day af ter  the pr imary operat ion) to stop b leeding  and to 
remove the hematoma. In one case, the source of  bleeding were  the epigastr ic 
vessels , in the second case the act ive source of  b leeding was  not found. 
Intraoperat ive uretera l  injury had occurred in the latter  pat ient,  caused by d if f icu lt ies 
wi th ureter iso lat ion and suspic ion of  a metastat ic LN in the project ion of  the ureter .  
Prompt d iagnos is of  the iatrogenic injury led to immediate ureter  neoimplantat ion by 
Boar i  technic , and intraoperat ive double-J catheter-s tent (6,32 Ch)  placement . 
Thereby we were able to avoid more ser ious compl icat ions,  such as an otherwise 
necessary reoperat ion.  
In one pat ient  (2.4%) a rectoves ical f is tu la was d iagnosed  af ter  surgery,  which 
required further surgery one month af ter  RP and par t ia l  resect ion of  the anter ior  
rectum wal l  wi th inser t ion of  a  protect ive double s igmoidostoma, and , a week later ,  
abdomen-per ineal c losure of  the f is tu la and suprapubic b ladder  dra inage insta l l ing. 
We suppose that  the previous RT in th is pat ient increased the r isk  of  such a 
compl icat ion, due to the t issue-changing proper t ies of  radiat ion . I t  must be kept  in  
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mind that surgical  preparat ion in pre- ir radiated pat ients  can lead to compl icat ions and 
intraoperat ive d if f icu l t ies.  
Two pat ients  (4.9%) developed postoperat ive lymphoceles, which required surgical 
treatment . Lymphoceles are not uncommon in pat ients af ter  RP (up to 20% in pr imary 
operat ions),  as wel l  as due to ePLND if  the deep lymphat ic vessels are touched upon.  
Lymphoceles lead to swel l ing, stagnat ion of  the l iqu id s, or  even thromboemboly of  
lower extremit ies . To prevent lymphoceles, the per i toneum is not fu l ly c losed, because 
i t  resorbs l iqu id –  thus surgeons make a fenestrat ion ( i .  e .  leave "windows" in  
per i toneum). Af ter the salvage operat ion we intent ional ly d id  not restore the integr i ty 
of  per i toneum, and therefore the number of  lymphoceles is  re lat ive ly smal l  in  
compar ison to pr imary RP. Moreover,  lymphocele correct ion is  now usual ly done 
laparoscopic at our  depar tment .  
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DISCUSSION 
We bel ieve that  there is  st i l l  no  treatment opt ion, which could prevent PCa re lapse. 
Therefore, the main a im in PCa t reatment is  to min imize these re lapses and to 
ef fect ive ly deal wi th c l in ica l ly evident recurrences. So far  the main treatment opt ions 
in case of  BCR have been ADT and/or RT. Salvage surgery (sRP resp.  SePLND) are 
rarely cons idered due to the lack of  data and the fear of  surg ical complicat ions.  
We studied the resul ts  of  PCa salvage  treatment in our inst i tu t ion.  25 (61.0%) pat ients 
were hormone resis tant at the t ime of  salvage surgery.  16 pat ients have not  received 
any ADT pr ior  to salvage surgery at a l l .  Although  the number of  pat ients is relat ive ly 
small ,  this s tudy has high c l in ica l re levance, due to the l im ited data on salvage 
treatment of  recurrent  PCa (Rigatt i  e t  a l.  2011, J i lg et a l .  2012) .  The pat ients were 
d ivided into three groups in order to evaluate the ef fect of  SePLND (resp. 
sRP+SePLND) on pat ients wi th d if ferent pr imary (Groups 1+2) and previous salvage 
treatment (Group 3) .  BRFS analysis is  one of  the key-points of  our study; the survival  
data are presented in a Kaplan-Maier curve (Diagram 13) .  According to our resul ts,  we 
are able to note some dif ferences between these groups.  
Thus, Group 1 (n=10) wi th sRP af ter pr imary RT, demonstrates surpr is ing resul ts af ter  
sRP: we observed BCRF in 60% of  the pat ients of  an average durat ion of  27.2 months ; 
50% of  the latter  cont inue to  have PSA levels of  below 0.5 ng/ml.  None of  these 
pat ients required fur ther salvage treatment, but prof i ted f rom adding only ADT in case 
of  PSA progress.  The iPSA level  was the h ighest in th is group:  a lmost  two t imes 
h igher than in the other two groups. This fact points to a more severe in it ia l  course of  
the oncological  process and increases the value of  the h igh treatment success rate  
achieved in  th is group in compar ison wi th the others groups .  
Analys is of  Group 2 (n=22; SePLND af ter  pr imary RP) a lso showed unexpectedly 
favourable resul ts .  This group wi th 22 out of  41 pat ients  (53.7%) was the largest one 
in our s tudy and demonstrates s imilar  results as Group 1 : 63.6% of  the pat ients 
achieved BCR-freedom with an average durat ion of  17.5 months, and 28.6% of  the 
lat ter  cont inue with  PSA levels under 0.5 ng/ml.  This BCRF-survival includes the data 
of  pat ients  who received ADT af ter  salvage surgery.  
In Group 3 (n=9;  SePLND af ter RP and sRT), BCRF was registered in 33.3% pat ients 
wi th an average durat ion of  27.2 months,  and 2 out of  the 3 la tter  pat ients  st i l l  have 
PSA levels  of  below 0.5 ng/ml.  Three other pat ients in th is group showed a PSA 
regress, but wi th levels over BCR cr i ter ia (0.5 ng/ml) .  The mean PSA-DT before ADT 
therapy in th is group was wi th 12.6 months h igher than in the previous two groups. 
The a im of  salvage treatment in Group 3 was to s top or min imize biochemical 
progress ion af ter  sRT by means of  sRP + SePNLD. Thus, 8 out  9 pat ients (88.9%) 
f rom Group 3 underwent SePLND af ter sRT. Retrospect ively,  sRT  in th is group of  
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pat ients may not have been the opt imal treatment choice, and in these cases i t  would 
have been better to perform  SePLND as soon as the PCa BCR was d iagnosed .  
The above-ment ioned resul ts of  sRP in Group 1 indicate the ro le of  SePLND, as a part  
of  sRP. The importance of  ePLND dur ing sRP is conf irmed by the fo l lowing f inding:  LN 
metastases were found in 15.0% of  a l l  removed LN dur ing sRP with SePLND and in 
14.7% of  a l l  removed LN dur ing SePLND alone. Therefore, as we have ment ioned 
before, the f requency of  metastases f inding dur ing salvage su rgery (summary sRP and 
SePLND) is a lmost  5.6 t imes higher than in pr imary RP (14.8% in salvage surgery vs .  
2.65% in pr imary RP respect ive ly) .  N1 s tage was establ ished af ter  58.3% of  a l l 
SePLND performed in our s tudy, which is more than 4 t imes more of ten than af ter  
pr imary RP.  
The number of  pos it ive LNs found dur ing pr imary RP seems to be an important fac tor 
for  CSS. This has been suggested by data f rom Bader and col leagues, which show a 
correlat ion between survival and the number of  pos i t ive LN s found dur ing pr imary RP 
with ePLND. Of  39 pat ients wi th only one pos it ive LN, 15 (39%) remained without 
s igns of  c l in ica l  or  chemical progress ion. On the other  hand, only 6 out  of  49 (12%) 
pat ients, who had at  least two pos it ive LNs, remained d isease-f ree (Bader et a l .  
2003).   
In general we suppose that the removal of  more LNs results in more pos it ive LNs that  
wi l l  be found (Osmonov et a l,  2013) .  Thus BRFS af ter ePLND is super ior  to lPLND as 
shown in a comparat ive study: t he 5-year PSA progress ion-f ree rate was 43% for 
ePLND versus 10% for lPLND (p=0.01) (Al la f  et a l,  2004) -  despite the s t i l l  re lat ive ly 
small  number  of  removed LNs in the ePLND group (mean 11.6 vs 8.9, p<0.0001).  
Compar ing the average number of  removed LNs in each group, we found that  the rate 
of  LN metastases detected in salvage procedures is much h igher  than in pr imary RP. 
Thus, dur ing pr imary RP only 7.8 LNs (2.65% LN+) per pat ient  were removed on 
average, whi le 18 LNs dur ing sRP (15% LN+), resp. 16.3 LNs dur ing SePLND (14. 7% 
LN+)  were removed per pat ient .  
More than every other LN (51.7%) removed dur ing pr imary RP was taken f rom the 
fossa obturator ia. Tradit ional ly,  most of  surgeons l im it  ePLND just to th is LN locat ion, 
cons ider ing that fur ther expans ion of  ePLND volume leads to an increase of  the 
number of  compl icat ions. But in  our s tudy among 117 obturator ic LN removed dur ing 
pr imary RP, just  in  3 (2.6%) metastases were found.  
Matte i and col leagues studied pr imary prostat ic lymphat ic landing s ites by us ing a 
mult imodal i t y technique and found that  PLND for  PCa should not only inc lude the 
external and obturator regions as wel l  as  the por t ions media l  and latera l to the 
internal i l iac vessels ,  but  a lso the common i l iac LN at  least  up to the ureter ic 
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cross ing. Thus i t  is  poss ib le to remove approx imately 75% of  a l l  nodes potent ial ly 
harbour ing metastas is  (Matte i et  a l .  2008).  
The f requency of  pos it ive LNs in our study increases with the number of  removed LNs 
per operat ion. These resul ts corre late wi th a paral le l study f rom our depar tment based 
upon 174 pat ients  (115 intermediate r isk  and 59 h igh r isk) ,  where results  of  a l l  
pr imary RPs are analysed. Our results have shown  that the more LNs are removed, 
the more metastases are found . Thus, the maximum number  of  metastases was 
detected only i f  more than 15 LNs were removed in the intermediate-r isk  and 18 LNs 
in h igh-r isk  group (Osmonov et  al .  2013) .  
The quest ion st i l l  remains  and cont inues to provoke controversy dur ing uro logy exper t 
meetings –  what should be the extent  of  LN dissect ion in PCa surgery? The 
prevalence of  metastases in the LNs of  paraaor ta l and communis  region in pat ients  
who have a PCa re lapse convinces us of  the necessi ty to perform a maximal ly 
extended ePLND, which inc ludes not only the fossa obturator ia, but also the a. i l iaca 
interna, ex terna and communis regions, the Marci l le tr iangle, the parasacral LNs, and 
even reaching into aorta b ifurcat ion area. I t  has been shown in previous studies f rom 
our department (Osmonov et a l.  2011) and has been proved again in the current 
study.   
We propose that at least 15 LNs in the intermediate-r isk  group and at least 18 LNs in 
the h igh-r isk  group should be removed dur ing ePLND. This is  only a re lat ive number  
and the actual number  of  removed LNs can a lso depend on fur ther  factors  such as  the 
condit ion of  the pat ient ,  the exper ience of  the surgeon, or the pr ior i t ies and spec if ics 
of  d if ferent surg ical  schools ( Osmonov et  a l .  2013,  Br igant i  e t a l.  2008) .  
However , i t  needs to be noted that we have a d if ferent s i tuat ion in salvage cases in 
compared to pr imary surgical treatment. A s ignif icant predominance of  posi t ive LNs in 
salvage surgery has c lear ly been shown by our data.   
Although salvage LN surgery fo l lows essent ia l ly the same surgical approach as 
pr imary ePLND, there are some dif ferences regarding the  h igher chal lenge to the 
surgeon as wel l  as the surgical outcome with respect to the number of  posi t ive LNs. A 
s ignif icant ly h igher rate of  posi t ive LNs in salvage surgery has c lear ly been shown by 
our  data.  
Moreover, the f requency of  LN metastases per  LN  group d if fers s ignif icant ly f rom the 
typical LN exc is ion areas in pr imary surgery. Dur ing the salvage procedure, we found 
only 4.4% LN metastases in the fossa obturator ia  –  less than in any other LN region. 
More than 50% of  a l l  LN metastases were found in  LNs of  the  a. i l iaca communis 
(29.9%) and in the LN group labeled “other LN” (23.7%), most ly cons is t ing of 
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paraaorta l,  paracaval  and aor tocaval LNs (s ituated above the typical area of  LN 
dissect ion) ,  as wel l  as  in ter i l iacal ,  promontor ium and mesenter ica l LNs.  
In a l l  three groups we were able to observe that the  PSA-DT increased af ter  ADT was 
star ted. ADT is an ef fect ive treatment opt ion which carr ies both good cancer contro l 
and c l in ica l  response in pat ients who were castrat ion -res istant pr ior  to salvage 
surgery.  
Therefore we have pointed out in the introduct ion that the BRFS af ter RP and RT are 
approx imately equal  (Table 1) .  
On the other hand,  salvage surgery can pro long  the t ime unt i l  ADT in it iat ion. ADT has 
of ten been shown to cause negat ive s ide ef fects such as loss of  l ib ido and fat igue, 
thus postponement of  ADT can help to improve t he qual i t y of  l i fe .  W e have found, 
moreover, that the moment of  hormone resistance is  observed at  a later t ime in 
salvage-operated pat ients. Unfortunate ly,  i t  is  not a lways poss ib le to determine the  
star t ing point and durat ion of  ADT, which makes i t  d i f f icu lt  to  draw a val id  conc lusion.  
Our data in conjunct ion with BCRF levels show that more than a half  pat ients can l ive  
in average near ly 2 years  wi thout  BCRF af ter  sal vage surgery of  recurrent  PCa    
(Table 3) .  W e consider the pro longat ion of  BRFS, CSS and the postponement of  ADT 
ini t ia t ion as the key-points of  our study as they i l lust rate the necess ity of  SePLND. 
The h igh r isk  of  LN metastases a lso documents the necess i ty to prevent metastat ic 
spread at an ear ly s tage of  the d isease, thus intermediate and h igh r isk  PCa pat ients 
ini t ia l ly should a lways undergo ePLND dur ing pr imary RP. Although PET -CT remains  
re levant ,  i t  is  not a safe method of  LN diagnost ics wi th a sensi t iv i ty/spec if ic i t y of  only 
85.1%/22.7% as shown in a recent analys is  (Osmonov et a l.  2013).  In the absence of  
re l iable preoperat ive d iagnost ics, ePLND and SePLND current ly remains the only 
method of  combatt ing LN metastat ic spread. Therefore, we bel ieve that refusal of  
SePLND cannot be jus t i f ied by fear of  compl icat ions .  
Some authors have pointed out that BCR f requency is in inverse rat io wi th an increase 
of  the radiat ion dose (Mohammed et a l .  2012).  In our opin ion, the long- term 
consequences and complicat ions of  h igh-dose radiat ion have not  been suf f ic ient ly 
examined yet .  I t  is  of ten imposs ib le to est imate the f requency and sever i ty of  h igh -
dose radiat ion compl icat ions due to  the required long- term fol low-up. Depending on 
the type of  RT, la te geni tour inary tox ic i t ies are present in ca. 21%-28% pat ients , la te 
gastrointest inal tox ic i t ies in 2% of  brachytherapy pat ients  and in up to 20% of  EBRT 
pat ients  (Mohammed et a l .  2012). The qual i ty of  l i fe and the general condit ion suf fers 
in these of ten o ld-age pat ients . In urological pract ice , radiat ion-caused cyst i t is  and 
proct i t is  have been observed at a mean fol low-up of  6-8 years af ter  RT (Osmonov et 
a l.  2006) .  
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Moreover, the ef fects  of  ionizing radiat ion on the tumor area and normal t issue in 
impact zone are a lso not fu l ly known current ly ,  and there are only scarce publ icat ions 
on th is issue (Ri ley 1994) .  The under lying logic of  re lapse emergence af ter  RT is 
based on the hypothes is  that v iable tumor cel ls  remain,  which are capable of 
uncontro l led d iv is ion,  lead ing to an oncological  progress ion. In our opin ion, the 
hypothes is that v iable tumor cel ls  remain in the body af ter  RT, requires fur ther 
conf irmat ion or refutat ion. In pract ice, th is is  a very d if f icu lt  issue because pat ients do 
not undergo prostate biopsy af ter  RT. I t  is  only indicated i f  the f inding of  a local 
recurrence af fec ts the treatment decis ion (Heidenreich et a l .  2012) .  The reason for 
th is has indirect ly been g iven  above: today BCR progress ( increase of  PSA level)  is 
seen as a synonym for PCa progress .  However, even i f  control b iops ies are 
performed, the above quest ion wi l l  remain unanswered, as i t  is  not possib le to 
h isto logical ly examine the ent ire volume  of  ir radiated t issue. Therefore, even i f  the 
b iopsy negat ive i t  is  not poss ib le to conc lude that there are no  v iable tumor cel ls  
(Serag et a l.  2012) .  
The above-ment ioned uncerta inty of  ce l l  s tatus af ter  RT remains a general problem 
which a lso appl ies to  pr imary PCa diagnost ics , espec ia l ly in the ear ly stages, when 
tumor cel ls  are of ten not detected in the f irst  or  even second biopsy, despite a r ise of  
PSA level .  Even i f  a PCa diagnos is is  achieved in one of  the subsequent  b iopsies , the 
tumor is g iven more t ime to progress whi le  the star t  of  treatment  is  delayed.  Extended 
and saturat ion b iopsy schemes should be performed fo l lowed by repeated b iops ies i f  
necessary (Scattoni  et  a l .  2007).   
When planning the salvage surgery, the pat ient ’s overal l  condit ion, h is PSA level,  GS, 
r isk  c lass if icat ion, PSA-DT should be taken into account.  In general ,  however, i t  
seems that salvage surgery should be considered as a val id treatment opt ion in a 
much larger share of  pat ients than to date , espec ia l ly when contrast ing the severe 
long-term fol low-up complicat ions af ter  RT ( radiat ion cyst i t is /proct i t is ,  b leedings) wi th 
the re lat ive ly l im ited and shor t - term compl icat ions assoc iated wi th salvage surgery.  
According to our  exper ience the number of  such compl icat ions  is  re lat ive ly small  ( in 
tota l  17.0%), which can expand the indicat ions for  performing salvage  surgery in  
pat ients wi th recurren t PCa and ePLND dur ing pr imary surgical  trea tment . W e would 
st i l l  l ike to emphasize  that the operat ion is re lat ive ly dif f icu lt  and should therefore be 
performed by an exper ienced surgeon.  Randomized c l inica l tr ia ls are necessary to 
determine the value of  d if ferent types of  salvage therapy.  
The improvements  of  RP technique dur ing the last  decade inc luding the new 
poss ib i l i t ies opened by robot -ass isted surgery have general ly reduced  the level of 
compl icat ions and of  long-term side ef fects . This a lso has implicat ions for  salvage 
surgery techniques. We have been able to show that sRP and SePLND are not  jus t 
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“PSA cosmetics” ,  but  ef f ic ient a lternat ives  and val id treatment opt ions in pat ients wi th 
PCa re lapse. The indicat ions for  sRP should be therefore expanded.   
Moreover, ePLND should be performed in a l l  cases both dur ing sRP as wel l  as  dur ing 
pr imary RP in pat ients  with in termediate - and h igh-r isk  prostate cancer wi th the a im of 
prevent ing cancer progress ion and metastasizing. We bel ieve that salvage surgery of 
pat ients wi th b iochemical PCa re lapse is feas ible and re lat ive ly safe  treatment  
method, that i t  pro longs the BRFS per iod, l i fe expectancy and cancer -spec if ic  survival 
in these pat ients.  
We real ize that the presented study has i t ’s  l im itat ions, such as the re lat ive ly low 
number of  pat ients included and the retrospect ive s ingle -center des ign.  Mult i -centr ic 
prospect ive randomized tr ia ls  are required.  
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SUMMARY 
Treatment of  pat ients  with  b iochemical PCa re lapse is general ly d if f icu l t  and without 
val id therapy opt ions. These pat ients commonly receive salvage RT (sRT) and/or ADT. 
A further  potent ia l t reatment  method is salvage extended PLND (SePLND). This 
treatment opt ion is s t i l l  rare ly performed and there are no re l iable long -term data.  We 
have retrospect ively analysed the outcome of  SePLND performed at our department 
s ince 2003 in 41 pat ients with a BCR. Moreover , we have performed an extens ive 
review of  the l i terature on salvage treatment  of  PCa recurrence.  
We divided the cohor t in to three groups according to the type of  pr imary treatment  
(Group1: pr imary RT; Group 2, pr imary RP; Group 3: pr imary RP+ sRT). Al l  41 
pat ients underwent SePLND; Group 1 addit ional ly underwent  sRP. Indicat ions for 
sa lvage treatment were BCR of  PCa and/or a  shor tening of  PSA-doubling t ime, a 
pos i t ive PET-CT scan, as wel l  as absence of  bone metastas is.  We observed PSA, 
PSA-veloc ity,  local izat ion of  LNs and LN+, BRFS, CSS and OS.  
There were 3 (7.5%) pat ients wi th low-r isk , 13 (32.5%) pat ients wi th intermediate -r isk 
and 24 pat ients (60.0%) wi th h igh-r isk  PCa. Thir ty (73.2%) f rom the tota l of  41  
pat ients received hormonal therapy at some stage before or af ter  salvage surgery. 
56.1% of  pat ients had an average BCRF-per iod of  21.4 months af ter  salvage surgery.  
This means that more than half  of  the pat ients were BCR-free for  almost 2 years .  
75.6% of  a l l  pat ients  showed a b iochemical regress , i .e .  a PSA drop-down af ter  
salvage surgery.  
The rate of  detected LN metastases was ca.  5.6 t imes h igher in salvage surgery than 
in pr imary RP (14.77% and 2.65% respect ive ly) .  The average number of  removed LNs 
per  pat ient  was 7.8 (0-36) dur ing pr imary RP, 16.6 (2-36) dur ing SePLND and 18.0 (9 -
26) dur ing sRP. W e suggest that i t  is  better  to remove the maximum possib le number 
of  LNs in the in i t ia l  procedure than to perform re-operat ions in the same pat ient due to 
later evidence of  LN metastases. Our proposal is  s trengthened by the fac t the  number 
of  sa lvage surgery complicat ions  was re lat ive ly smal l  (17.0%) . We bel ieve that our 
resul ts  c lear ly under l ine  the necess i t y of  ePLND and SePLND respect ive ly.  
Due to the re lat ively small  number of  pat ients  we cannot at th is stage recommend 
SePLND implementat ion in a l l  pat ients  wi th BCR. In absence of  a control  group, i t  can 
so far only be stated that  SePLND is  a feasible and re lat ive ly safe treatment opt ion 
and has a promising outcome. SePLND can pro long BCRF survival  and postpone ADT 
ini t ia t ion, whi le i ts  inf luence on CSS remains yet unclear. W e bel ieve that more data 
wi l l  be accumulated  in the future  in mult i -center randomized prospect ive studies. On 
th is bas is the ro le of  sa lvage surgery can be more c lear ly def ined and enhanced. I t  
wi l l  a lso be necessary to develop c lear  recommendat ions for  salvage  surgery and to 
def ine the indicat ions.  Ul t imately,  i t  wi l l  he lp to treat pat i ents  with recurrent  PCa more 
ef fect ive ly,  to  pro long the l i fe  of  these pat ients , and to reduce PCa morta l i t y.  
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SUPPLEMENT (Graphic material) 
 
Figure 1. Estimated cancer new cases and deaths in  a) USA (according to Cancer Statistics 
2010) and b) Schleswig-Holstein (Germany) 
 
a  b 
 
 
Figure 2. 11C-choline PET/CT. Suspicion of left-side pelvine LN metastasis. 
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Figure 3. Pelvine scintigramm. Suspicion of left-side pelvine LN metastasis. 
 
 
 
 
Figure 4. Groups of LNs, removed during ePLND. 
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Figure 5. Three groups of patients, n=41. 
 
 
Table 1. 5-year BRFS level after RP vs. RT treatment of PCa. 
 
 Low-risk Intermediate-r isk High-risk 
Radical 
prostatectomy 
85-94% 68-77% 55-(68**)% 
Radiotherapy 66-86% 51-78% 29-(67*)% 
*  -  10 -years  BRFS  
**-  15-years  BRFS 
 
(The table reflects the results from the following studies: Partin et al. 1993, Catalona et al. 1994, 
Zincke et al. 1994, Paulson et al. 1994, Kuban et al. 1995, Zietmann et al. 1995, Khuntia et al. 
2004, Sylvester et al. 2006, Bastide et al. 2006, Hernandez et al. 2007, Yoshioka et al. 2009, 
Burdick et al. 2009, Loeb et al. 2010.) 
 
Table 2. Median age at moment of treatment in each patient group (age range). 
 
Groups of patients 
 
Age (yrs) at time of 
primary treatment salvage treatment 
 
RT            sRP (Group1) 
64.2 ± 3.6 (60-70) 68.2 ± 4.1 (63-76) 
 
RP           SePLND  (Group2) 
61.8 ± 7.2 (52-74) 65.2 ± 7.5 (54-78) 
 
RP         sRT         S ePLND   (Group3) 
61.4 ± 7.6 (52-73) 66.0 ± 6.7 (54-74) 
Summary 62.3 ± 8.7 (49-74) 66.1 ± 6.5 (54-78) 
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Table 3. Results after Salvage treatment in all three groups (n=41). 
 
 n 
BCR-free patients  
after salvage 
Biochemical 
regress  
Mean BCR-
free period 
(months) 
Patients with 
ADT 
Group 1 10 60.0% 70.0% 27.2 40.0% 
Group 2 22 63.6% 82.1% 17.5 40.7% 
Group 3 9 33.3% 66.6% 17.7 44.4% 
 
 
Table 4. Results after salvage treatment: patients with- vs. without ADT. 
 Patients with ADT Patients without ADT 
 
BCR-free 
patients 
after salvage 
BCR-free 
period  
(months) 
PSA-DT  
(months) 
BCR-free patients 
after salvage 
BCR-free 
period  
(months) 
PSA-DT  
(months) 
Group 1 50.0% 26.5 7.0 66.7% 27.5 4,5 
Group 2 81.8% 16.8 9.0 60.0% 13.0 6.1 
Group 3 75.0% 17.7 - 0% - 12.6 
 
Table 5. Complications of salvage treatment (n=41). 
 
Complication Frequency 
Intra-/early postoperative period 
Bleeding 2 (4.9%) 
Ureteral injury 1 (2.4%) 
Late postoperative period 
Lymphocele 2 (4.9%) 
Ureteral stricture 1 (2.4%) 
Rectovesical fistula 1 (2.4%) 
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Diagram 1. Distribution of patients in groups and follow-up (n=41). 
   
Diagram 2. Gleason score in all patients (n=41). 
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
30,0%
35,0%
40,0%
45,0%
Gleason score
Gleason score 9,8% 43,9% 17,1% 22,0% 2,4% 4,9%
6 7 8 9 10 ?
 
 
 
Median Follow-up 
(months) 
Group 1 40.0 ± 11.2 
Group 2  32.2  ± 27.0 
Group 3 60.2 ± 24.5 
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Diagram 3. Risk groups according to D’Amico classification in all patients (n=41). 
 
Diagram 4. iPSA level in all patients groups (n=41). 
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Diagram 5. Dynamic of PSA-DT in months. 
 
 
 
Diagram 6. Localisation of LN Metastasis (in all 41 patients after sRP and SePLND in a total 
of 46 salvage operations). Average of removed LNs per operation: 16.6. n=765 (LNs in total). 
 
 
 
 
 
 
 
 
 
 
* interiliacal (26/4), paraaortal (43/16), paracaval (6/5), promontorium (6/2), mesenterical (3/0) 
 
LNs+ / LNs 
total n LNs 
1. Total LNs 14.77% 765 
2. External LNs 12.21% 172 
3. Internal LNs 12.09% 91 
4. Obturatoric LNs 4.31% 116 
5. Communis LNs 17.89% 190 
6. Presacral LNs 15.38% 65 
7. Triangle Marcille 
LNs 10.00% 50 
8. Other LNs* 32.14% 84 
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Diagram 7. Localisation of LN metastasis (in all 41 patients after sRP and SePLND in a total 
of 46 salvage operations). n=113 (LNs+ in total) 
 
 
Diagram 8. Frequency of N1 stage after all operations. 
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Diagram 9. Total number of removed LNs in different operations (n=991 LNs). 
 
 
Diagram 10. Frequency of positive LNs in all operations (n=991 LN). 
 
 
50 
 
 
Diagram 11. Correlation between the number of removed LNs per operation and frequency 
of positive LNs.  
 
 
 
Diagram 12. Types of radiotherapy used in study. 
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Diagram 13. Kaplan-Meier curve with analysis of BRFS in 3 groups (n=41). 
Biochemical recurrence-free surv iv al after salv age ePLND (n=41)
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